Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Telli ML, et al. Among authors: hartman ar. Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8. Clin Cancer Res. 2016. PMID: 26957554 Free PMC article. Clinical Trial.
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM. Telli ML, et al. Among authors: hartman ar. J Clin Oncol. 2015 Jun 10;33(17):1895-901. doi: 10.1200/JCO.2014.57.0085. Epub 2015 Apr 6. J Clin Oncol. 2015. PMID: 25847929 Free PMC article. Clinical Trial.
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. Isakoff SJ, et al. Among authors: hartman ar. J Clin Oncol. 2015 Jun 10;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660. Epub 2015 Apr 6. J Clin Oncol. 2015. PMID: 25847936 Free PMC article. Clinical Trial.
Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
Afghahi A, Timms KM, Vinayak S, Jensen KC, Kurian AW, Carlson RW, Chang PJ, Schackmann E, Hartman AR, Ford JM, Telli ML. Afghahi A, et al. Among authors: hartman ar. Clin Cancer Res. 2017 Jul 1;23(13):3365-3370. doi: 10.1158/1078-0432.CCR-16-2174. Epub 2017 Jan 13. Clin Cancer Res. 2017. PMID: 28087643 Free PMC article. Clinical Trial.
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML, Hellyer J, Audeh W, Jensen KC, Bose S, Timms KM, Gutin A, Abkevich V, Peterson RN, Neff C, Hughes E, Sangale Z, Jones J, Hartman AR, Chang PJ, Vinayak S, Wenstrup R, Ford JM. Telli ML, et al. Among authors: hartman ar. Breast Cancer Res Treat. 2018 Apr;168(3):625-630. doi: 10.1007/s10549-017-4624-7. Epub 2017 Dec 23. Breast Cancer Res Treat. 2018. PMID: 29275435
BRCA1 and p53: compensatory roles in DNA repair.
Hartman AR, Ford JM. Hartman AR, et al. J Mol Med (Berl). 2003 Nov;81(11):700-7. doi: 10.1007/s00109-003-0477-0. Epub 2003 Sep 9. J Mol Med (Berl). 2003. PMID: 13679996 Review.
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, Timms K, Garber JE, Herold C, Ellisen L, Krejdovsky J, DeLeonardis K, Sedgwick K, Soltis K, Roa B, Wenstrup RJ, Hartman AR. Tung N, et al. Among authors: hartman ar. Cancer. 2015 Jan 1;121(1):25-33. doi: 10.1002/cncr.29010. Epub 2014 Sep 3. Cancer. 2015. PMID: 25186627 Free article.
Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.
Bueno R, Hughes E, Wagner S, Gutin AS, Lanchbury JS, Zheng Y, Archer MA, Gustafson C, Jones JT, Rushton K, Saam J, Kim E, Barberis M, Wistuba I, Wenstrup RJ, Wallace WA, Hartman AR, Harrison DJ. Bueno R, et al. Among authors: hartman ar. J Thorac Oncol. 2015 Jan;10(1):67-73. doi: 10.1097/JTO.0000000000000365. J Thorac Oncol. 2015. PMID: 25396679 Free PMC article.
105 results